Thymic carcinoma surgery

Revision as of 18:36, 10 September 2019 by Marjan Khan (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Thymic Carcinoma Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thymic carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Thymic carcinoma surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Google Images

American Roentgen Ray Society Images of Thymic carcinoma surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thymic carcinoma surgery

CDC on Thymic carcinoma surgery

Thymic carcinoma surgery in the news

Blogs on Thymic carcinoma surgery

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Thymic carcinoma surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]

Overview

Surgery is the mainstay of treatment for thymic carcinoma.[1]

Surgery

Treatment options for thymic carcinoma include the following:[1]

  • Surgery
  • Radiation
  • Cisplatin-based chemotherapy
  • For patients with clinically resectable disease, surgical resection is often the initial therapeutic intervention.
  • For clinically borderline or frankly unresectable lesions, neoadjuvant (preoperative) chemotherapy or thoracic radiation therapy, or both, is given.
  • Patients presenting with locally advanced disease should be carefully evaluated and undergo multimodality therapy.
  • Patients with poor performance status and high associated operative risks are generally not considered for these types of aggressive treatments.
  • Patients with metastatic disease may respond to combination chemotherapy.

References

  1. 1.0 1.1 National Cancer Institute. General Information About Thymoma and Thymic Carcinoma Treatment. http://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq. Accessed on 22nd December, 2015.